Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pre-existing antibody and T cell responses to SaCas9, AsCas12a and CasΦ are comparable in naïve individuals.

Nature communications·2026
Same author

Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape.

Frontiers in immunology·2026
Same author

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

Experimental hematology & oncology·2026
Same author

Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors.

Molecular therapy. Oncology·2025
Same author

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.

Journal of hematology & oncology·2025
Same author

MHC II MAPPs for High-Confident Immunogenicity Risk Assessment of Biotherapeutics.

Methods in molecular biology (Clifton, N.J.)·2025

相关实验视频

Updated: Sep 19, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.1K

一个基于mRNA的工作流程,通过HLA-I/亲和力净化验证新表位表现.

Arthur Esprit1, Dorien Autaers1, Kris Thielemans1

  • 1Translational Oncology Research Centre, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Frontiers in immunology
|June 19, 2025
PubMed
概括

这项研究引入了一种基于mRNA的工作流程,以精确净化和识别人类白细胞抗原 (HLA) - 化合物. 这种方法有助于通过抗原呈现细胞 (APC) 验证癌症新表位表现,用于个性化癌症疫苗.

关键词:
这就是IVT-mRNA.标志性 标志性 标志性 标志性质谱测量质谱测量质谱测量质谱测量质量测量质谱测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量呈现方式 呈现方式净化 净化 净化 净化

更多相关视频

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

13.0K
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

14.9K

相关实验视频

Last Updated: Sep 19, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.1K
Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
09:32

Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis

Published on: October 15, 2021

13.0K
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

14.9K

科学领域:

  • 免疫学 免疫学 免疫学
  • 分子生物学分子生物学
  • 癌症研究 癌症研究

背景情况:

  • 有效的癌症疫苗依赖于向细胞毒性T淋巴细胞呈现人类白细胞抗原 (HLA) 类I限制新表位.
  • 通过抗原呈现细胞 (APCs) 验证新表位呈现对于推进个性化癌症疗法至关重要.
  • 目前的新表位物识别方法往往耗时且计算密集.

研究的目的:

  • 评估基于mRNA的工作流程,以精确净化HLA-I- (pHLA) 复合体.
  • 为了使用液体染色学-并联质谱法 (LC-MS/MS) 方便精确的标识.
  • 为了证明这个工作流在验证APCs的新表位表现方面的潜力.

主要方法:

  • 使用编码双条纹标签 (TST) 的mRNA与特定的HLA-I分子 (HLA-TST) 融合,用于基于亲和力的净化.
  • 编码TST-HLA-A*02:01和HLA-A*02:01受限表位的同电化mRNA被转化为HLA-A*02:01阴性APC.
  • 通过使用LC-MS/MS.从pHLA复合体中净化并识别出传递的表位.

主要成果:

  • 通过基于mRNA的HLA-TST方法,成功净化了pHLA复合体.
  • 通过LC-MS/MS证明了通过LC-MS/MS检测到传递的表位.
  • 证实了在APC中验证新表位表现的可行性.

结论:

  • 开发的基于mRNA的工作流提供了一种精确的方法来净化和识别HLA-复合体.
  • 这种方法对于在个性化癌症疫苗的背景下验证新表位表现具有重大潜力.
  • 需要进行进一步的研究,以优化通过LC-MS/MS来识别的技术变量.